🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  2. A study to find a suitable dose of ASP5834 in adults with solid tumors

    Astellas Pharma GmbH

    Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification

    phase 1 other active

    1 trial

  3. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  4. A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies

    Lacuna Pharma Pty Ltd

    B-Cell Non-Hodgkin’s Lymphoma (B-NHL)

    phase 1 other active

    1 trial

  5. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  6. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  7. APR-246

    Aprea Therapeutics

    Myeloid Malignancy

    phase 1 small molecule completed

    1 trial

  8. APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

    Pyxis Oncology

    Glioblastoma Multiforme

    phase 1 mab active

    1 trial

  9. AZD5492

    AstraZeneca AB

    B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  10. AdV-tk

    Candel Therapeutics

    Glioma, Malignant

    phase 1 mab completed

    1 trial

  11. AdV-tk

    Candel Therapeutics

    Malignant Glioma

    phase 1 mab completed

    2 trials

  12. AdV-tk + valacyclovir

    Candel Therapeutics

    Malignant Pleural Effusion

    phase 1 mab completed

    1 trial

  13. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  14. Aflibercept (AVE0005)

    Regeneron UK Limited

    Neoplasm Malignant

    phase 1 small molecule completed

    2 trials

  15. Allo-depleted lymphocyte infusion

    Lxo Ireland Designated Activity Company

    Transplant-Related Hematologic Malignancy

    phase 1 other terminated

    1 trial

  16. Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  17. Atumelnant

    Crinetics Pharmaceuticals Europe GmbH

    Healthy Volunteers

    phase 1 small molecule active

    2 trials

  18. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Mature B-cell Malignancies

    phase 1 small molecule active

    1 trial

  19. BNT314

    BioNTech SE

    Advanced or metastatic malignant solid tumors

    phase 1 small molecule active

    1 trial

  20. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial

  21. Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  22. Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  23. Biological: ProHema-CB

    Zafatek

    Hematologic Malignancies

    phase 1 mab terminated

    1 trial

  24. Brentuximab Vedotin

    Takeda

    Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources